Pfizer

CenterWatch Monthly April 2009

Friday, April 10, 2009 08:00 AM

Pfizer’s Enhanced Clinical Trial Design Saves $100 Million Annually

More... »

Pfizer is First Pharma Company to Receive AAHRPP Accreditation

Tuesday, April 7, 2009 08:00 AM

Pfizer is the first pharmaceutical company to be accredited by the Association for the Accreditation of Human Research Protection Programs. Pfizer (and its phase I clinical research units) was among 16 organizations to receive accreditation this quarter, bringing the total number of AAHRPP-accredited organizations to 175.

More... »

CenterWatch Monthly March 2009

Thursday, March 5, 2009 08:00 AM

Pharma Consolidation Slows CRO Market in Short Term

More... »

Pfizer Plans to Disclose Payments Made to Clinical Investigators

Tuesday, February 17, 2009 02:13 AM

Pfizer plans to publicly report payments made to clinical investigators, physicians and other healthcare professionals by early next year, making it the first pharmaceutical company to commit to disclosing payments it makes for conducting clinical trials, speaking and consulting.

More... »

Lowered Guidance Won’t Stop Covance

Monday, January 5, 2009 09:10 AM

Global contract research organization (CRO) Covance ended the year with a flurry, lowering its 2008 guidance, purchasing an equity stake in a proteomics biomarker services provider and adding four executive positions.

More... »

Covance Names New Periapproval Services Executives

Monday, December 29, 2008 11:15 AM

Global contract research organization (CRO) Covance has added three new senior executive positions to its periapproval services team. The Princeton, N.J.-based company appointed Glynis Neagle, M.D., vice president for medical affairs; Robert Bader, director for product safety services; and Thomas Noto, vice president for regulatory affairs.

More... »

WuXi Revenues Up 98%, Still Fall Short

Thursday, November 13, 2008 10:14 AM

WuXi Pharmatech released final third quarter earnings that reflected 98% revenue growth year-over-year but fell short of the company’s projected Q3 earnings.

More... »

Pfizer HIV Treatment Sees Positive Results

Monday, August 6, 2007 06:24 AM

Pfizer reported positive results from a phase III trial of maraviroc for the treatment of HIV. This 48-week trial was dubbed MERIT (maraviroc versus Efavirenz Regimens as Initial Therapy) and enrolled CCR5-tropic HIV-1 infected subjects who had never received antiretroviral therapy and had no evidence of resistance to the drugs used in the study. MERIT was designed to compare maraviroc (300 mg twice daily) to efavirenz, standard of care, (600 mg once daily), both dosed in combination with zidovudine/lamivudine.

More... »

Painless Growth?

Monday, October 9, 2006 07:21 AM

Big Pharma continues to expand into the vaccine market as Pfizer purchased privately owned PowderMed this week, hoping for an ouch-free entry into this segment. The vaccine market is suddenly looking golden to Big Pharma when just a few years ago it seemed that most drugmakers wouldn’t go near vaccines.

More... »

Clinical Research in India

Tuesday, July 11, 2006 01:18 PM

Posted by:  Dr. Chandrashekhar Potkar

More... »